Compare UAA & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAA | SRPT |
|---|---|---|
| Founded | 1996 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | N/A | 1997 |
| Metric | UAA | SRPT |
|---|---|---|
| Price | $5.77 | $21.07 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 28 |
| Target Price | $6.18 | ★ $25.68 |
| AVG Volume (30 Days) | ★ 15.3M | 2.9M |
| Earning Date | 02-06-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,049,070,000.00 | $2,413,715,000.00 |
| Revenue This Year | N/A | $13.99 |
| Revenue Next Year | $1.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.15 |
| 52 Week Low | $4.13 | $10.42 |
| 52 Week High | $8.72 | $120.05 |
| Indicator | UAA | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 47.33 |
| Support Level | $5.39 | $20.94 |
| Resistance Level | $5.81 | $23.00 |
| Average True Range (ATR) | 0.29 | 1.28 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 79.59 | 23.53 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.